| Name | EPI-589 |
|---|
| Description | EPI-589, a quinone derivative, is a safe and well tolerated oxidoreductase enzyme inhibitor. EPI-589 has the potential for the treatment of amyotrophic lateral sclerosis (ALS)[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: oxidoreductase enzyme[1] |
| In Vivo | EPI-589 exhibits a significant improvement in cerebrospinal fluid (CSF) and plasma-based biomarkers known to be associated with neuroinflammation and ALS disease progression[2]. |
| References |
[1]. BioElectron’s EPI-589 Shows Positive Results in ALS Patients in Phase 2a Trial [2]. Phase IIa trial of EPI-589 in ALS shows improvement in CSF |
| Molecular Formula | C14H19NO4 |
|---|---|
| Molecular Weight | 265.30 |